These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Fife BT; Bluestone JA Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926 [TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. Cho H; Kang H; Lee HH; Kim CW Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703774 [TBL] [Abstract][Full Text] [Related]
4. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925 [TBL] [Abstract][Full Text] [Related]
5. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer]. Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783 [TBL] [Abstract][Full Text] [Related]
7. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer]. Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005 [TBL] [Abstract][Full Text] [Related]
8. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A. Cho H; Kang H; Kim CW; Kim HY; Jang JW; Yoon SK; Lee CD Gut Liver; 2016 Mar; 10(2):288-94. PubMed ID: 26347518 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810 [TBL] [Abstract][Full Text] [Related]
11. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034 [TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Weber J Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057 [TBL] [Abstract][Full Text] [Related]
14. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. Kassardjian A; Shintaku PI; Moatamed NA PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601 [TBL] [Abstract][Full Text] [Related]
15. [The expressions of CTLA-4 and PD-1 on CD(4)(+) T cells and the level of plasma VEGF in patients with obstructive sleep apnea hypopnea syndrome]. Liu YL; Luo SH; Ou Q; Yuan P; Lu MZ; Chen JN; Luo ZR; Lao MC; Cui JH; Gao XL Zhonghua Jie He He Hu Xi Za Zhi; 2019 Apr; 42(4):268-274. PubMed ID: 30955284 [No Abstract] [Full Text] [Related]
19. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. Boer MC; van Meijgaarden KE; Goletti D; Vanini V; Prins C; Ottenhoff TH; Joosten SA Tuberculosis (Edinb); 2016 Mar; 97():163-71. PubMed ID: 26750180 [TBL] [Abstract][Full Text] [Related]
20. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]